Research ExplorerPublicationsBasiliximab induction therapy in kidney transplantation: Ben...

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Standard

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years? / Koch, Martina; Becker, Thomas; Lueck, Rainer; Neipp, Michael; Klempnauer, Juergen; Nashan, Björn.

In: BIOL-TARGETS THER, Vol. 3, 2009, p. 51-56.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Koch, M, Becker, T, Lueck, R, Neipp, M, Klempnauer, J & Nashan, B 2009, 'Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?', BIOL-TARGETS THER, vol. 3, pp. 51-56. https://doi.org/10.2147/btt.2009.2781

APA

Koch, M., Becker, T., Lueck, R., Neipp, M., Klempnauer, J., & Nashan, B. (2009). Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years? BIOL-TARGETS THER, 3, 51-56. https://doi.org/10.2147/btt.2009.2781

Vancouver

Koch M, Becker T, Lueck R, Neipp M, Klempnauer J, Nashan B. Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years? BIOL-TARGETS THER. 2009;3:51-56. https://doi.org/10.2147/btt.2009.2781

Bibtex

@article{27a7c0c1a9704c7fa6a66b90b455b680,
title = "Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?",
abstract = "The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.",
author = "Martina Koch and Thomas Becker and Rainer Lueck and Michael Neipp and Juergen Klempnauer and Bj{\"o}rn Nashan",
year = "2009",
doi = "10.2147/btt.2009.2781",
language = "Deutsch",
volume = "3",
pages = "51--56",
journal = "BIOL-TARGETS THER",
issn = "1177-5475",
publisher = "DOVE MEDICAL PRESS LTD",

}

RIS

TY - JOUR

T1 - Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

AU - Koch, Martina

AU - Becker, Thomas

AU - Lueck, Rainer

AU - Neipp, Michael

AU - Klempnauer, Juergen

AU - Nashan, Björn

PY - 2009

Y1 - 2009

N2 - The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.

AB - The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.

U2 - 10.2147/btt.2009.2781

DO - 10.2147/btt.2009.2781

M3 - SCORING: Zeitschriftenaufsatz

VL - 3

SP - 51

EP - 56

JO - BIOL-TARGETS THER

JF - BIOL-TARGETS THER

SN - 1177-5475

ER -